Kerri Fitzgerald

Cancer Nursing Today nonprod

A study published in Transplant and Cellular Therapy assessed outcomes in patients with myelofibrosis (MF) who choose to under hematopoietic cell transplant (HCT) versus non-transplant therapies. They found that white patients were more likely to identify a well-matched donor. There was no survival difference between upfront HCT versus non-transplant therapy; however, more patients in the HCT arm were in remission at last follow-up.Researchers sought to identify patient, disease, and donor-related factors that influence HCT decisions in patients with MF, as well as compare survival in patients who elect upfront HCT versus non-transplant therapy.The retrospective chart review included 183 patients aged younger than 70 years. Of this cohort, 129 (70%) developed an HCT indication. Age &gt;60 years was significantly associated with higher rates of human leukocyte antigen (HLA)-typing refusal (n=13/72 vs. n=1/44; P=0.02). White patients had an increased rate of identifying well-matched donors compared with non-white patients (75% vs. 48%; P=0.02).Among the 102 patients who were HLA typed, 93% found a potential donor. Sixty-nine patients (68%) found a well-matched donor, and 25 (25%) found a mismatched donor/haplo-identical related; the remaining eight patients (8%) found no donor. Among the 69 patients with well-matched donors, 34 (49%) did not pursue upfront HCT despite an indication for transplant. Despite availability of a well-matched donor, a significant proportion of patients with MF who had a transplant indication did not pursue HCT.After a median follow-up of 3.2 years (range, 0.5-8.0 years), the researchers observed no difference in survival between patients who underwent upfront HCT versus those who received non-transplant therapies, although more patients were in remission in the HCT arm at the last follow-up.&ldquo;These findings emphasize the importance of patient education when discussing HCT in MF, as well as emphasizing individual goals of care, particularly within older-age patients,&rdquo; the researchers concluded.

Transplant Trends in Patients With Myelofibrosis

Myelofibrosis

A study assessed outcomes in patients with myelofibrosis (MF) who choose to under hematopoietic cell transplant (HCT) versus non-transplant therapies.

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe